1 week TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates Zacks

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -7.41% and 53.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?